Novartis AG
Pharmaceutical Compositions and Pharmaceutical Products of Heterodimeric Human Interleukin-15 (hetIL-15)

Abstract:

The disclosure is directed to stable pharmaceutical compositions comprising a heterodimer complex of IL-15 and IL-15R.alpha. and pharmaceutical products comprising such compositions. The disclosure is also directed to the use of these compositions (e.g. as part of a kit having instructions for use) and pharmaceutical products for the treatment of lymphopenia, cancer, or infectious disease.